Merck said worldwide sales for Q3 2026 were $18,085 million, up 5% from a year earlier (4% excluding foreign exchange). Sales of KEYTRUDA/KEYTRUDA QLEX rose 6% to $8,601 million, of which KEYTRUDA QLEX accounted for $830 million.

1. 01

   Merck said worldwide sales for Q3 2026 were $18,085 million, up 5% from a year earlier (4% excluding foreign exchange). Sales of KEYTRUDA/KEYTRUDA QLEX rose 6% to $8,601 million, of which KEYTRUDA QLEX accounted for $830 million.

2. 02

   The company said GAAP EPS for Q3 2026 was $2.04 ($2.32 a year earlier), and non-GAAP EPS was $2.49 ($2.58 a year earlier). Both figures include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch.

3. 03

   Merck said GAAP gross margin for Q3 2026 was 72.9%, down from 77.7% a year earlier, citing higher amortization of intangible assets, restructuring costs and production costs. R&D expenses rose 7% to $4.5 billion, and the company attributed the increase in part to a $400 million charge related to SciBrunch.

4. 04

   Merck presented its full-year 2026 sales outlook as $66.8 billion to $67.3 billion (prior outlook $66.3 billion to $67.3 billion). Its non-GAAP EPS outlook is $2.77 to $2.82 (previously $2.66 to $2.76), and includes a one-time charge of $0.12 related to SciBrunch.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.